Skip to main content
Erschienen in: Medical Oncology 4/2012

01.12.2012 | Original Paper

Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia

verfasst von: Umran Kucukgoz Gulec, Semra Paydas, Ahmet Baris Guzel, Selim Buyukkurt, Gulsah Seydaoglu, Mehmet Ali Vardar

Erschienen in: Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the diagnostic role of the CA 125, ferritin, beta-2 microglobulin (β2 M), and lactic dehydrogenase (LDH) levels in serum and peritoneal fluid (PF) in patients with ovarian neoplasms. Using cross-sectional study design; serum and PF CA 125, ferritin, β2 M, and LDH levels were analyzed in 40 patients with benign ovarian neoplasms (Group 1) and 59 patients with malignant ovarian neoplasms (Group 2) which were evaluated surgically. Serum and PF levels of these markers compared between the groups. Diagnostic role of these markers were determined with receiver operating curve (ROC) analysis. Serum and PF CA 125, ferritin, β2 M, and LDH levels were statistically significant higher in patients with ovarian cancers as compared with benign neoplasms. Among these biomarkers, PF β2 M levels had highest sensitivity and specificity, 76.3 and 85%, respectively with the cut-off value: 2.3 mg/l. This study results indicates that especially PF β2 M and ferritin levels may be valuable for diagnosis of malignant ascites in patients with ovarian neoplasms.
Literatur
2.
Zurück zum Zitat Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol. 2011;2011:475983.PubMedCrossRef Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol. 2011;2011:475983.PubMedCrossRef
3.
Zurück zum Zitat Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996;62:384–9.PubMedCrossRef Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996;62:384–9.PubMedCrossRef
4.
Zurück zum Zitat Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267–77.PubMedCrossRef Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267–77.PubMedCrossRef
5.
Zurück zum Zitat Molina R, Filella X, Jo J, Ballesta AM. CA 125 in biological fluids. Int J Biol Markers. 1998;13:224–30.PubMed Molina R, Filella X, Jo J, Ballesta AM. CA 125 in biological fluids. Int J Biol Markers. 1998;13:224–30.PubMed
6.
Zurück zum Zitat Finch CA, Bellotti V, Stray S, Lipschitz DA, Cook JD, Pippard MJ, Huebers HA. Plasma ferritin determination as a diagnostic tool. West J Med. 1986;145(5):657.PubMed Finch CA, Bellotti V, Stray S, Lipschitz DA, Cook JD, Pippard MJ, Huebers HA. Plasma ferritin determination as a diagnostic tool. West J Med. 1986;145(5):657.PubMed
7.
Zurück zum Zitat Schneider D, Halperin R, Langer R, et al. Peritoneal fluid lactate dehydrogenase in ovarian cancer. Gynecol Oncol. 1997;66:399–404.PubMedCrossRef Schneider D, Halperin R, Langer R, et al. Peritoneal fluid lactate dehydrogenase in ovarian cancer. Gynecol Oncol. 1997;66:399–404.PubMedCrossRef
8.
Zurück zum Zitat Yuce K, Baykal C, Genc C, Al A, Ayhan A. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynecol Oncol. 2001;22(3):228–32. Yuce K, Baykal C, Genc C, Al A, Ayhan A. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynecol Oncol. 2001;22(3):228–32.
9.
Zurück zum Zitat Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003;3:952–61.PubMedCrossRef Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003;3:952–61.PubMedCrossRef
10.
Zurück zum Zitat Algarra I, Collado A, Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res. 1997;27:95–102.PubMedCrossRef Algarra I, Collado A, Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res. 1997;27:95–102.PubMedCrossRef
11.
Zurück zum Zitat Cabrera T, López-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother. 2003;52(1):1–9.PubMed Cabrera T, López-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother. 2003;52(1):1–9.PubMed
12.
Zurück zum Zitat Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol. 2000;77:254–7.PubMedCrossRef Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol. 2000;77:254–7.PubMedCrossRef
13.
Zurück zum Zitat Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75:264–5.PubMedCrossRef Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75:264–5.PubMedCrossRef
14.
Zurück zum Zitat Sedlaczek P, Frydecka I, Gabryś M, Van Dalen A, Einarsson R, Harłozińska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer. 2002;95(9):1886–93.PubMedCrossRef Sedlaczek P, Frydecka I, Gabryś M, Van Dalen A, Einarsson R, Harłozińska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer. 2002;95(9):1886–93.PubMedCrossRef
15.
Zurück zum Zitat Tuzun Y, Celik Y, Bayan K, Yilmaz S, Dursun M, Canoruc F. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt? J Int Med Res. 2009;37(1):79–86.PubMed Tuzun Y, Celik Y, Bayan K, Yilmaz S, Dursun M, Canoruc F. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt? J Int Med Res. 2009;37(1):79–86.PubMed
16.
Zurück zum Zitat Halperin R, Hadas E, Bukovsky I, Schneider D. Peritoneal fluid analysis in the differentiation of ovarian cancer and benign ovarian tumor. Eur J Gynaecol Oncol. 1999;20(1):40–4.PubMed Halperin R, Hadas E, Bukovsky I, Schneider D. Peritoneal fluid analysis in the differentiation of ovarian cancer and benign ovarian tumor. Eur J Gynaecol Oncol. 1999;20(1):40–4.PubMed
17.
Zurück zum Zitat Yinnon A, Konijn AM, Link G, Moreb J, Hershko C. Diagnostic value of ferritin in malignant pleural and peritoneal effusions. Cancer. 1988;62(12):2564–8.PubMedCrossRef Yinnon A, Konijn AM, Link G, Moreb J, Hershko C. Diagnostic value of ferritin in malignant pleural and peritoneal effusions. Cancer. 1988;62(12):2564–8.PubMedCrossRef
18.
Zurück zum Zitat Tripathi PK, Chatterjee SK. Elevated expression of ferritin H-chain mRNA in metastatic ovarian tumor. Cancer Invest. 1996;14(6):518–26.PubMedCrossRef Tripathi PK, Chatterjee SK. Elevated expression of ferritin H-chain mRNA in metastatic ovarian tumor. Cancer Invest. 1996;14(6):518–26.PubMedCrossRef
19.
Zurück zum Zitat Pinto V, Marinaccio M, Garofalo S, Vittoria Larocca AM, Geusa S, Lanzilotti G, et al. Preoperative evaluation of ferritinemia in primary epithelial ovarian cancer. Tumori. 1997;83(6):927–9.PubMed Pinto V, Marinaccio M, Garofalo S, Vittoria Larocca AM, Geusa S, Lanzilotti G, et al. Preoperative evaluation of ferritinemia in primary epithelial ovarian cancer. Tumori. 1997;83(6):927–9.PubMed
20.
Zurück zum Zitat Paydas S, Sargin O, Ozbek S, Gürbüz E. Ferritin levels in malignant effusions: a useful marker?. Eur J Cancer. 1990;26(8):919.PubMed Paydas S, Sargin O, Ozbek S, Gürbüz E. Ferritin levels in malignant effusions: a useful marker?. Eur J Cancer. 1990;26(8):919.PubMed
21.
Zurück zum Zitat Demirkazik A, Dinçol D, Hastürk S, Arican A, Karaoguz H, Cay F, Içli F. Diagnostic value of ferritin in the differential diagnosis of malignant effusions. Cancer Biochem Biophys. 1998;16(3):243–51.PubMed Demirkazik A, Dinçol D, Hastürk S, Arican A, Karaoguz H, Cay F, Içli F. Diagnostic value of ferritin in the differential diagnosis of malignant effusions. Cancer Biochem Biophys. 1998;16(3):243–51.PubMed
22.
Zurück zum Zitat Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer. 1983;32(5):547–54.PubMedCrossRef Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer. 1983;32(5):547–54.PubMedCrossRef
23.
Zurück zum Zitat Rolland P, Deen S, Scott I, Durrant L, Spendlove I. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res. 2007;13(12):3591–6.PubMedCrossRef Rolland P, Deen S, Scott I, Durrant L, Spendlove I. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res. 2007;13(12):3591–6.PubMedCrossRef
Metadaten
Titel
Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia
verfasst von
Umran Kucukgoz Gulec
Semra Paydas
Ahmet Baris Guzel
Selim Buyukkurt
Gulsah Seydaoglu
Mehmet Ali Vardar
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0165-4

Weitere Artikel der Ausgabe 4/2012

Medical Oncology 4/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.